This phase II trial studies how well letermovir works for the prevention of cytomegalovirus
reactivation in patients with hematological malignancies treated with alemtuzumab. Patients
receiving treatment with alemtuzumab may experience cytomegalovirus reactivation. Letermovir
may block cytomegalovirus replication and prevent infection.
I. To estimate the rate of cytomegalovirus (CMV) reactivation in patients treated with
letermovir at 3 months after completion of alemtuzumab therapy.
I. To evaluate the tolerability of letermovir in combination with alemtuzumab.
II. To evaluate the efficacy of letermovir for the prevention of clinically significant CMV
III. To estimate the progression free survival of patients in the study population.
IV. To estimate the overall survival of patients in the study population.
I. To evaluate mechanisms of antiviral resistance in letermovir prophylaxis failures.
Beginning within 7 days of the first administration of standard alemtuzumab, patients receive
letermovir orally (PO) (or intravenously [IV] over 1 hour if patient is unable to take PO for
an extended period of time) daily on days 1-28. Cycles repeat every 28 days for up to 3
months after the last dose of alemtuzumab in the absence of unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.